The effect of treatment with the oral growth hormone (GH) secretagogue MK-677 on GH isoforms

Growth Hormone and IGF Research

Volumn 13, Issue 1, 2003, Pages 1-7

  Svensson, J ^a   Boguszewski, C L ^b   Shibata, F ^b   Carlsson, B ^a   Carlsson, L M S ^a   Bengtsson, B A ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

20 kDa growth hormone; Growth hormone isoforms; Growth hormone secretagogue; Growth hormone secretion; Non 22kDa growth hormone

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE SECRETAGOGUE; IBUTAMOREN; PLACEBO;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HORMONE DETERMINATION; HUMAN; MALE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0037291122     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-6374(02)00138-7     Document Type: Article

References (41)

1. C. Bowers, F. Momany, D. Chang, A. Hong, K. Chang, Structure-activity relationships of a synthetic pentapeptide that specifically releases GH in vitro, Endocrinology 106 (1980) 663-667.
2. F. Momany, C. Bowers, G. Reynolds, A. Hong, K. Newlander, Conformational energy studies and in vitro activity data on active GH releasing peptides, Endocrinology 114 (1984) 1531-1537.
3. C. Bowers, A. Sartor, G. Reynolds, T. Badger, On the actions of the growth hormone-releasing hexapeptide, GHRP-6, Endocrinology 128 (1991) 2027-2035.
4. E. Ghigo, E. Arvat, E. Gianotti, et al., Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man, J. Clin. Endocrinol. Metab. 78 (1994) 693-698.
5. M. Korbonits, A. Grossman, Growth hormone-releasing peptide and its analogues. Novel stimuli to growth hormone release, Trends Endocrinol. Metab. 6 (1995) 43-49.
6. R. Smith, L. Van Der Ploeg, A. Howard, et al., Peptidomimetic regulation of growth hormone secretion, Endocr. Rev. 18 (1998) 621-645.
7. A. Howard, S. Feighner, D. Cully, et al., A pituitary gland and hypothalamic receptor that functions in growth hormone release, Science 273 (1996) 974-977.
8. M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, K. Kangawa, Ghrelin is a growth-hormone-releasing acylated peptide from stomach, Nature 402 (1999) 656-660.
9. G. Baumann, Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins, Endocr. Rev. 12 (1991) 424-429.
10. U. Lewis, J. Dunn, L. Bonefeld, B. Seavy, W. Vanderlaan, A naturally occurring structural variant of human growth hormone, J. Biol. Chem. 253 (1978) 2679-2687.
11. U. Lewis, L. Bonewald, L. Lewis, The 20,000 Da variant of human growth hormone: location of the amino acid deletions, Biochem. Biophys. Res. Commun. 92 (1980) 511-516.
12. F. DeNoto, D. Moore, H. Goodman, Human growth hormone DNA sequence and mRNA structure: possible alternative splicing, Nucleic Acids Res. 9 (1981) 3719-3739.
13. U. Lewis, E. Markoff, F. Culler, A. Hayek, W. Vanderlaan, Biologic properties of the 20kDa variant of human growth hormone: a review, Endocrinol. Jpn. 34 (supp 1) (1987) 73-84.
14. H. Uchida, N. Naito, N. Asada, et al., Secretion of authentic 20 kDa human growth hormone (20K hGH) in Escherichia coli and properties of the purified product, J. Biotechnol. 55 (1997) 101-112.
15. M. Wada, M. Ikeda, Y. Takahashi, et al., The full agonistic effect of recombinant 20 kDa human growth hormone (hGH) on CHO cells stably transfected with hGH receptor cDNA, Mol. Cell Endocrinol. 133 (1997) 99-107.
16. J. Kostyo, A. Skottner, P. Brostedt, et al., Biological characterization of purified native 20-kDa human growth hormone, Biochim. Biophys. Acta 925 (1987) 325-331.
17. M. Wada, H. Uchida, M. Ikeda, et al., The 20 kDa human growth hormone (hGH) differs from the 22 kDa hGH in the complex formation with cell surface hGH receptor and hGH-binding protein circulating in human plasma, Mol. Cell Endocrinol. 12 (1997) 146-156.
18. B. Tsunekawa, M. Wada, M. Ikeda, H. Uchida, N. Naito, M. Honjo, The 20-kilodalton (kDa) human growth hormone hGH differs from the 22-kDa hGH in the effect on the human prolactin receptor, Endocrinology 140 (1998) 3909-3918.
19. Y. Hashimoto, T. Kamioka, M. Hosaka, et al., Exogenous 20K growth hormone (GH) suppresses endogenous 22K GH secretion in normal men, J. Clin. Endocrinol. Metab. 85 (2000) 601-606.
20. R. Singh, B. Seavey, L. Lewis, U. Lewis, Human growth hormone peptide 1-43: isolation from pituitary glands, J. Protein Chem. 2 (1983) 525-536.
21. G. Baumann, M. Shaw, Plasma transport of the 20,000-Da variant of growth hormone (20K): evidence for a 20K-specific binding site, J. Clin. Endocrinol. Metab. 71 (1990) 1339-1343.
22. J. McCarter, M. Shaw, L. Winer, G. Baumann, The 20,000 Da variant of human growth hormone does not bind to growth hormone receptors in human liver, Mol. Cell Endocrinol. 73 (1990) 11-14.
23. U. Lewis, L. Lewis, M. Salem, N. Staten, S. Galosy, G. Krivi, A recombinant DNA-derived modification of human growth hormone (hGH44-191) with enhanced diabetogenic activity, Mol. Cell Endocrinol. 78 (1991) 45-54.
24. B. Cunningham, M. Ultsch, A. De Vos, M. Mulkerrin, K. Clauser, J. Wells, Dimerization of the extracellular domain of the human growth hormone receptor by a single growth hormone molecule, Science 254 (1991) 821-825.
25. A. De Vos, M. Ultsch, A. Kossiakof, Human growth hormone and extracellular domain of its receptor: Crystal structure of the complex, Science 255 (1992) 306-312.
26. G. Fuh, B. Cunningham, R. Fukunaga, S. Nagata, D. Goeddel, J. Wells, Rational design of potential antagonists to the human growth hormone receptor, Science 256 (1992) 1677-1680.
27. V. Goffin, K. Shiverick, P. Kelly, J. Martial, Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen, and related proteins in mammals, Endocr. Rev. 17 (1996) 385-410.
28. S. Rowlinson, M. Walters, U. Lewis, R. Barnard, Human growth hormone fragments 1-43 and 44-191: in vitro somatogenic activity and receptor-binding characteristics in human and non-primate systems, Endocrinology 137 (1996) 90-95.
29. G. Baumann, M. Stolar, Molecular forms of human growth hormone secreted in vivo: nonspecificity of secretory stimuli, J. Clin. Endocrinol. Metab. 62 (1986) 789-790.
30. F. Roelfsema, D. Van der Heide, P. Lowry, H. Van Dulken, J. Schröder-Vander Elst, Plasma growth hormone after selective removal of adenoma in acromegalics determines the outcome of surgery, Clin. Endocrinol. 28 (1998) 51-59.
31. M. Arosio, M. Nissim, M. Ballabio, R. Orefice, N. Bazzoni, G. Faglia, Size heterogeneity of circulating growth hormone in acromegaly: "big-big" GH forms are associated with inappropriately low IGF-I values, Acta Endocrinol. 125 (1991) 150-159.
32. C. Campino, J. Szekowka, J. Lopez, M. Seron-Ferre, Bioactive GH-like immunoglobulins G in acromegaly: response to long-term treatment with bromocriptine, Clin. Endocrinol. 43 (1994) 111-116.
33. C. Boguszewski, G. Johannsson, B.-Å. Bengtsson, A. Johansson, B. Carlsson, L. Carlsson, Circulating non-22kDa growth hormone isoforms in acromegalic men before and after transsphenoidal surgery, J. Clin. Endocrinol. Metab. 82 (1997) 1516-1521.
34. T. Tsushima, Y. Katoh, Y. Miyachi, et al., Serum concentration of 20K human growth hormone (20K hGH) measured by a specific enzyme-linked immunosorbent assay, J. Clin. Endocrinol. Metab. 84 (1999) 317-322.
35. J. Svensson, L. Lönn, J.-O. Jansson, et al., Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure, J. Clin. Endocrinol. Metab. 83 (1998) 362-369.
36. C. Boguszewski, L. Hynsjö, G. Johannsson, B.-Å. Bengtsson, L. Carlsson, 22-kDa growth hormone exclusion assay: a new approach to measurement of non-22-kDa growth hormone isoforms in human blood, Eur. J. Endocrinol. 135 (1996) 573-582.
37. The international standard for growth hormone, human: for bioassay. 80/505. 1982. Holly Hill, Hampstead, UK, London National Institute for Biological Standards and Controls.
38. F. Cordido, A. Penalva, C. Dieguez, F. Casanueva, Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: Evidence for a marked somatotroph secretory capability in obesity, J. Clin. Endocrinol. Metab. 76 (1993) 819-823.
39. J. Svensson, C. Ohlsson, J.-O. Jansson, et al., Treatment with the oral growth hormone secretagofue MK-677 increases markers of bone formation and bone resorption in obese young males, J. Bone Miner. Res. 13 (1998) 1158-1166.
40. J. Svensson, B. Carlsson, L. Carlsson, J.-O. Jansson, B.-Å. Bengtsson, Discrepancy between serum leptin values and total body fat in response to the oral growth hormone (GH) secretagogue MK-677, Clin. Endocrinol. 50 (1999) 451-456.
41. J. Svensson, J.-O. Jansson, M. Ottosson, et al., Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a), J. Clin. Endocrinol. Metab. 84 (1999) 2028-2033.